Products

What will AGI do for Amisometradine?

This classification denotes a diuretic with the molecular formula C9H13N3O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 30973N61ZF, chemically known as 2,4(1h,3h)-pyrimidinedione, 6-amino-3-methyl-1-(2-methyl-2-propenyl)- (9ci) but generally known as amisometradine, which bears US NIH Compound Identifier 11071. European Medicines Agency schedules Amisometradine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05457MIG. The term AMISOMETRADINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13, No. 12, 1959, List 3). AMISOMETRADINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule amisometradine under HS 29335995 and SITC 51576. As of Q4 2014, AMISOMETRADINE remains the US FDA Preferred Term for this commodity. Amisometradine bears US NLM identifiers UMLS ID C0301545 and NCI Concept Code C76646. SMILES: O=C1N(CC(=C)C)C(N)CC(=O)N1C.

How AGI delivers it

Four ways AGI delivers for Amisometradine

  • Headless SaaS for Agents

    Give your tools an agent-consumable surface (API / MCP / SDK) so agents can do the work.

    For Amisometradine, give your tools an agent-consumable surface (API / MCP / SDK) so agents can do the work.

  • Services-as-Software

    Get the professional outcome delivered as software, priced on results, not headcount.

    For Amisometradine, get the professional outcome delivered as software, priced on results, not headcount.

Value flow

How Amisometradine connects

measured by

  • Active Ingredient Potencymodel
  • Compound Puritymodel
  • Melting Pointmodel
  • Residual Solventmodel